DEM Program Sample Clauses

DEM Program. Commencing on the Effective Date until expiration of the DEM Option Term, the Parties will conduct the DEM Program in accordance with the DEM IDP with the goal of [***], including the achievement of the [***] Criteria, to prepare the applicable Data Package. The DEM IDP is attached hereto as Exhibit D-1. Commencing on the Effective Date until expiration of the DEM Option Term, and prior to Celgene’s exercise of the Option for the DEM Program, OncoMed may [***] of DEM Product Candidates [***], provided OncoMed first consults the JSC prior to [***] and reasonably considers the JSC’s comments with respect thereto. Commencing on the Effective Date until expiration of the DEM Option Term, and prior to Celgene’s exercise of the Option for the DEM Program, in the event that Celgene desires to [***] with respect to any DEM Product Candidate for [***], it shall consult with and obtain the consent of the JSC prior to [***]; provided, that the foregoing shall not apply to [***] or, [***].
Sample 1
AutoNDA by SimpleDocs
DEM Program. The Target for the DEM Program is DLL4.
Sample 1
DEM Program. Solely in the event Celgene does not exercise its Option with respect to the DEM Program within the DEM Option Term, upon expiration of the DEM Option Term, (a) all rights granted by OncoMed to Celgene with respect to the DEM Program, including all rights granted by OncoMed to Celgene with respect to DEM Product Candidates (including Demcizumab), shall revert to OncoMed, and (b) Celgene shall return to OncoMed, or destroy, at OncoMed’s option, all Confidential Information and/or Materials provided by OncoMed to Celgene in relation to the DEM Program during the Term prior to the date of expiration of the DEM Option Term, unless related to another then-existing Program, and Section 11.7 shall apply. For clarity, notwithstanding anything to the contrary in this Section 2.6.1 and Section 11.7, Section 5.1.3 shall apply, as provided therein.
Sample 1
DEM Program. With respect to the DEM Program, OncoMed hereby grants to Celgene an exclusive option, exercisable at any time during the DEM Option Term, to enter into a Co-Development and Co-Commercialization Agreement with respect to the DEM Product Candidates (including Demcizumab) and any related Diagnostic Products developed therefor, as set forth in and on the terms and conditions set forth in such agreement, the form of which is attached hereto as Exhibit B (and in such case DLL4 shall be deemed the “Co-Co Target” thereunder and the DEM Product Candidates shall be deemed “Co-Co Candidates” thereunder); provided, that if OncoMed exercises its right to opt-out of its co-Development and co-Commercialization rights with respect to the DEM Program pursuant to Section 3.1.4, then the Parties shall enter into a License Agreement with respect to the DEM Product Candidates and any related Diagnostic Products developed therefor, as set forth in and on the terms and conditions set forth in such agreement, the form of which is attached hereto as Exhibit A (and in such case DLL4 shall be deemed the “Licensed Target” thereunder and the DEM Product Candidates shall be deemed “Licensed Candidates” thereunder).
Sample 1
DEM Program. In the event the Licensed Program is the DEM Program, then the financial terms set forth on Exhibit C-1 shall apply.
Sample 1
DEM Program. In the event the Co-Co Program is the DEM Program, then the financial terms set forth on Exhibit C-1 shall apply.
Sample 1
DEM Program. In consideration for the rights and licenses granted to Celgene under this Co-Co Agreement with respect to the Co-Co Program (where such Co-Co Program is the DEM Program):
Sample 1
AutoNDA by SimpleDocs

Related to DEM Program

  • Training Program It is agreed that there shall be an Apprenticeship Training Program, the provisions of which are set forth in Exhibit "D", which is attached hereto and forms part of this Agreement.

  • Apprenticeship Program The parties agree to meet to discuss the development of mutually agreeable apprenticeship programs. The specific provisions of the apprenticeship programs shall be subject to agreement between the City, the Civil Service Commission (where appropriate), and the Union. Each apprenticeship program, however, shall contain at least the following terms:

  • Program 3.01. The Borrower declares its commitment to the Program and its implementation. To this end, and further to Section 5.08 of the General Conditions: (a) the Borrower and the Bank shall from time to time, at the request of either party, exchange views on the Borrower’s macroeconomic policy framework and the progress achieved in carrying out the Program; (b) prior to each such exchange of views, the Borrower shall furnish to the Bank for its review and comment a report on the progress achieved in carrying out the Program, in such detail as the Bank shall reasonably request; and (c) without limitation upon the provisions of paragraphs (a) and (b) of this Section, the Borrower shall promptly inform the Bank of any situation that would have the effect of materially reversing the objectives of the Program or any action taken under the Program including any action specified in Section I of Schedule 1 to this Agreement.

  • Pilot Programs The Employer may develop voluntary pilot programs to test the acceptability of various risk management programs. Incentives for participation in such programs may include limited short-term improvements to the benefits outlined in this Article. Implementation of such pilot programs is subject to the review and approval of the Joint Labor-Management Committee on Health Plans.

  • Safety Program The Contractor shall design a specific safety program for the Work for the site(s). The Contractor shall establish and require all Subcontractors to establish reasonable safety programs. The Contractor shall also submit its standard monthly safety reports to the Owner and Design Professional. No imposition of responsibility on the Contractor for safety under this Contract shall relieve any subcontractor of its responsibility for safety of persons or property on or near the Project Site. The Contractor shall include in his plant he names of the person in charge of Safety.

  • Project Implementation Manual The Recipient, through the PCU, shall: (i) take all action required to carry out Parts 1.1, 1.3, 1.4, 2, 3.1(b), 3.2, 3.3 and 4 (ii) of the Project in accordance with the provisions and requirements set forth or referred to in the Project Implementation Manual; (ii) submit recommendations to the Association for its consideration for changes and updates of the Project Implementation Manual as they may become necessary or advisable during Project implementation in order to achieve the objective of Parts 1.1, 1.3, 1.4, 2, 3.1(b), 3.2, 3.3 and 4(ii) of the Project; and (iii) not assign, amend, abrogate or waive the Project Implementation Manual or any of its provisions without the Association’s prior agreement. Notwithstanding the foregoing, if any of the provisions of the Project Implementation Manual is inconsistent with the provisions of this Agreement, the provisions of this Agreement shall prevail and govern.

  • Program Review The State ECEAP Office will conduct a review of each contractor’s compliance with the ECEAP Contract and ECEAP Performance Standards every four years. The review will involve ECEAP staff and parents. After the Program Review, the State ECEAP Office will provide the contractor with a Program Review report. The contractor must submit an ECEAP Corrective Action Plan for non-compliance with ECEAP Performance Standards. The Plan must be approved by the State ECEAP Office.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Quality Assurance Program An employee shall be entitled to leave of absence without loss of earnings from her or his regularly scheduled working hours for the purpose of writing examinations required by the College of Nurses of Ontario arising out of the Quality Assurance Program.

  • Training Programs All employees shall successfully complete all necessary training prior to being assigned work (e.g., all employees will complete health and safety training prior to being assigned to task). Nothing in this Article or provision shall constitute a waiver of either party’s bargaining obligations or defenses. The Employer still has an obligation to notify and bargain changes in terms and conditions of employment with the exclusive representative.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!